Table 5 Five most enriched gene ontology (GO) processes and KEGG pathway of up-regulated mRNAs in Alzheimer’s disease model.
From: Possible epigenetic regulatory effect of dysregulated circular RNAs in Alzheimer’s disease model
7 months | 12 months | ||||
|---|---|---|---|---|---|
GO biological process | Fold Enrichment | P value | GO biological process | Fold Enrichment | P value |
Macrophage colony-stimulating factor signaling pathway | 70.1 | 0.028 | T cell activation via T cell receptor contact with antigen bound to MHC molecule on APC | 69.3 | 0.028 |
Cellular response to L-glutamine | 46.7 | 0.042 | Negative regulation of myeloid dendritic cell activation | 52.0 | 0.038 |
Positive regulation of serotonin secretion | 46.7 | 0.042 | Positive regulation of tumor necrosis factor secretion | 52.0 | 0.038 |
Positive regulation of thyroid hormone generation | 46.7 | 0.042 | Negative regulation of natural killer cell activation | 52.0 | 0.038 |
Response to aldosterone | 46.7 | 0.042 | Positive regulation of interleukin-1 production | 41.6 | 0.047 |
GO molecular function | GO molecular function | ||||
Fc-gamma receptor I complex binding | 49.5 | 0.040 | C-X3-C chemokine binding | 41.8 | 0.047 |
Beta-glucuronidase activity | 37.1 | 0.033 | Transforming growth factor beta-activated receptor activity | 34.8 | 0.006 |
Superoxide-generating NADPH oxidase activity | 27.8 | 0.005 | Lipoteichoic acid binding | 34.8 | 0.006 |
Enhancer sequence-specific DNA binding | 8.6 | 0.047 | Fibronectin binding | 10.8 | 0.031 |
RNA polymerase II transcription factor binding | 6.7 | 0.006 | — | — | — |
GO cellular component | GO cellular component | ||||
CSF1-CSF1R complex | 71.2 | 0.028 | integrin complex | 16.6 | 0.002 |
Alphav-beta3 integrin-IGF-1-IGF1R complex | 35.6 | 0.055 | immunological synapse | 15.3 | 0.020 |
NADPH oxidase complex | 23.7 | 0.007 | phagocytic vesicle membrane | 8.9 | 0.010 |
Sperm midpiece | 10.7 | 0.031 | receptor complex | 5.4 | 0.002 |
Integrin complex | 8.5 | 0.047 | external side of plasma membrane | 3.6 | 0.001 |
Pathway analysis | Pathway analysis | ||||
Glycosaminoglycan degradation | 9.5 | 0.038 | Graft-versus-host disease | 37.4 | 0.028 |
Complement and coagulation cascades | 7.0 | <0.001 | Allograft rejection | 34.4 | 0.038 |
Osteoclast differentiation | 6.9 | <0.001 | Type I diabetes mellitus | 31 | 0.042 |
Staphylococcus aureus infection | 6.7 | 0.006 | Intestinal immune network for IgA production | 29.6 | 0.047 |
Hematopoietic cell lineage | 6.3 | <0.001 | — | — | — |
